Get the Stockscreener App
36.11
6.67%
-2.58
After Hours:
36.10
-0.010
-0.03%
Structure Therapeutics Inc Adr stock is traded at $36.11, with a volume of 740.53K.
It is down -6.67% in the last 24 hours and down -28.85% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$38.69
Open:
$38.63
24h Volume:
740.53K
Relative Volume:
0.81
Market Cap:
$2.57B
Revenue:
-
Net Income/Loss:
$-141.43M
P/E Ratio:
-14.69
EPS:
-2.4581
Net Cash Flow:
$-226.41M
1W Performance:
-5.77%
1M Performance:
-28.85%
6M Performance:
+4.67%
1Y Performance:
+43.46%
1-Day Range:
$35.78
$38.63
1-Week Range:
$35.78
$40.00
52-Week Range:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
36.11 | 2.75B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Globe and Mail
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Motley Fool
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position - AOL.com
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure? - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
GPCR Stock Price, Quote & Chart | STRUCTURE THERAPEUTICS INC (NASDAQ:GPCR) - ChartMill
Understanding Momentum Shifts in (GPCR) - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Brokers Offer Predictions for GPCR Q1 Earnings - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
GPCR Structure posts massive EPS miss as losses widen; stock barely flinches, down 0.13%.Product Revenue - newser.com
Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects - Sahm
Structure Therapeutics Reports 16% Weight Loss With Oral GLP-1RA Aleniglipron in Phase 2, Prepares for Phase 3 Obesity Trial and ADA 2026 Data Presentations - Minichart
Pier Capital LLC Sells 148,752 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program - TipRanks
Structure Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) funds obesity drug push with $1.46B cash - Stock Titan
Obesity drug gains momentum as Structure (NASDAQ: GPCR) eyes Phase 3, boosts ATM - Stock Titan
Obesity pill developer posts 16.3% weight loss, targets Phase 3 - Stock Titan
GPCR (NASDAQ: GPCR) expands ATM program to $400M capacity - Stock Titan
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed? - Sahm
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics (GPCR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Structure Therapeutics Reports Weight Loss Success in Obesity Drug Trial - HarianBasis.co
Universal Beteiligungs und Servicegesellschaft mbH Buys 67,338 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Canaccord Genuity Group to Strong-Buy Rating - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics (GPCR) Leerink Global Healthcare Conference 2025 Summary - Quartr
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Five obesity and diabetes studies from Structure Therapeutics head to ADA - Stock Titan
Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Pullback - Sahm
Peregrine Capital Management LLC Buys Shares of 84,324 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
[ARS] Structure Therapeutics Inc. SEC Filing - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) details 2026 virtual shareholder meeting - Stock Titan
Structure Therapeutics (GPCR) COO & GC Matthew Lang files initial Form 3 - Stock Titan
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Discipline and Rules-Based Execution in GPCR Response - Stock Traders Daily
Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy? - Sahm
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
FMR LLC funds trim 17,452 Structure Therapeutics (GPCR) ADS holdings - Stock Titan
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill - TradingView
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results? - TradingView
Structure Therapeutics Appoints Matthew Lang as COO and General Counsel to Advance Obesity Drug Pipeline - Minichart
Structure Therapeutics stock rating maintained at Outperform by Leerink - Investing.com
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):